RELENZA, an influenza neuraminidase inhibitor, is indicated for:Treatment of influenza in patients 7 years of age and older who have been symptomatic for no more than 2 days.

(1.1)Prophylaxis of influenza in patients 5 years of age and older.

(1.2)Important Limitations on Use of RELENZA:Not recommended for treatment or prophylaxis of influenza in:Individuals with underlying airways disease.

(5.1)Not proven effective for:Treatment in individuals with underlying airways disease.

(1.3)Prophylaxis in nursing home residents.

(1.3)Not a substitute for annual influenza vaccination.

(1.3)

---

Influenza -- acute viral infection involving the respiratory tract; marked by inflammation of the nasal mucosa, the pharynx, and conjunctiva, and by headache and severe, often generalized, myalgia.

Do not use in patients with history of allergic reaction to any ingredient of RELENZA including lactose (which contains milk proteins) [see Warnings and Precautions (5.2), Description (11)].

---

Allergic Reaction --

Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.